Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT

Author:

Ryan Christine E.1,Sahaf Bita1,Logan Aaron C.2,O’Brien Susan3,Byrd John C.4,Hillmen Peter5,Brown Jennifer R.6,Dyer Martin J. S.7,Mato Anthony R.89,Keating Michael J.3,Jaglowski Samantha4,Clow Fong10,Rezvani Andrew R.1,Styles Lori10,Coutre Steven E.1,Miklos David B.1

Affiliation:

1. Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA;

2. Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA;

3. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;

4. The Ohio State University Medical Center, Columbus, OH;

5. St. James Institute of Oncology, The Leeds Teaching Hospitals, West Yorkshire, United Kingdom;

6. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA;

7. Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom;

8. Center for CLL, University of Pennsylvania, Philadelphia, PA;

9. Hackensack University Medical Center, Hackensack, NJ; and

10. Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA

Abstract

Key Points Ibrutinib provided effective salvage therapy in CLL relapse post–alloHCT, resulting in sustained MRD negativity without GVHD development. Ibrutinib selectively depleted pre–germinal B cells and Th2 helper cells and may enhance donor Th1 T-cell–mediated GVL effects.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3